InfuSystem Holdings, Inc.

InfuSystem Holdings is a US and Canadian medical-device services company — provides infusion pumps and related medical devices on a rental / recurring-revenue basis to hospitals, home care, and specialty pharmacy customers. The recurring-revenue model produces stable cash generation with modest but consistent growth.

The mechanics of the setup:

• Q2 revenue was $36.9M, up 2.6% YoY and 9.6% QoQ — modest growth continuing.
• Q2 EPS was $0.15 versus $0.105 expected — a 42.9% beat, the largest recent surprise magnitude.
• Q3 EPS estimate for November 3 is $0.14 — flat sequentially.
• Q2 gross margin at 58% and operating margin at 11.2% reflect the recurring-revenue-services model economics.
• Q2 free cash flow was $8.4M — supportive cash generation.
• At $247M market cap and 29x TTM P/E the multiple is stretched for a modest-growth healthcare-services name; the forward multiple on the Q2 EPS trajectory is more reasonable.
• Free cash flow yield 8.9% and 15.8x EV/EBITDA reflect meaningful value characteristics.
• D/E 0.39 is conservative — balance sheet is not the constraint.
• ROIC 13% and ROE 14.8% — solid returns on capital.
• The absence of aggregated X sentiment reflects sparse retail interest in this specific microcap.

The path from here is defined by the November 3 Q3 print — the acid test on whether the Q2 EPS beat is durable. Continued mid-single-digit revenue growth + margin expansion + FY guidance raise re-rates toward $16; a growth deceleration or margin compression resets to $10. Hospital-services capex trends provide the sector overlay.